Precision BioSciences, Inc.

Now that Precision Biosciences has received Clinical Trial Application approval for its PBGENE-HBV program, what's next? Join us virtually on Friday, November 15, at 7am PST / 10am EST, for a Hepatitis B Investor Event featuring key opinion leaders, members of Precision’s Hepatitis Scientific Advisory Board, and the executive management team for a discussion on the current unmet need, treatment landscape, a deeper dive into Precision’s PBGENE-HBV preclinical safety data, and Phase 1 clinical trial plans! For more information and registration, visit https://loom.ly/igX-DhU #GeneEditing #Biotech #DTIL #HBV

📢 First Clinical Trial Application (CTA) Approval Received! Precision BioSciences received its first approval for a CTA to initiate a first-in-human study of PBGENE-HBV to treat chronic Hepatitis B. Precision remains laser-focused on execution, and our first CTA approval for PBGENE-HBV represents another significant milestone as we complete our transition to a clinical stage in vivo gene editing company. The Company has opened the Phase 1 clinical program and is moving towards dosing patients. For more information, visit https://loom.ly/5uS0qi0. #GeneEditing #Biotech #DTIL #HBV

Precision President & CEO, Michael Amoroso, will participate in the Longwood Boston CEO Conference's Expanding Platform Potential panel on Monday, October 28 at 11:10 AM ET. For more information, visit https://loom.ly/DrdDgfE. #GeneEditing #Biotech #DTIL #HBV

We're another step closer to a potentially curative therapy for Chronic Hepatitis B! Today, Precision BioSciences announced the submission of Clinical Trial Applications (CTA) to initiate a Phase 1 study evaluating PBGENE-HBV. PBGENE-HBV is the Company’s wholly-owned in vivo gene editing program designed to potentially cure chronic hepatitis B virus (HBV) by eliminating cccDNA, the key source of replicating hepatitis B virus, while also inactivating integrated HBV DNA in hepatocytes. These regulatory submissions are the culmination of our team’s dedication, commitment and highly productive interactions with global regulators as we develop the first clinical stage in vivo gene editing program for chronic hepatitis B virus, recognized as one of the largest global public health problems by the World Health Organization with an estimated 300 million people afflicted globally. For more information, read our latest press release, https://loom.ly/z_AysCM. #GeneEditing #Biotech #DTIL #HBV

We're another step closer to a potentially curative therapy for Chronic Hepatitis B! Today, Precision BioSciences announced the submission of Clinical Trial Applications (CTA) to initiate a Phase 1 study evaluating PBGENE-HBV. PBGENE-HBV is the Company’s wholly-owned in vivo gene editing program designed to potentially cure chronic hepatitis B virus (HBV) by eliminating cccDNA, the key source of replicating hepatitis B virus, while also inactivating integrated HBV DNA in hepatocytes. These regulatory submissions are the culmination of our team’s dedication, commitment and highly productive interactions with global regulators as we develop the first clinical stage in vivo gene editing program for chronic hepatitis B virus, recognized as one of the largest global public health problems by the World Health Organization with an estimated 300 million people afflicted globally. For more information, read our latest press release, https://loom.ly/z_AysCM. #GeneEditing #Biotech #DTIL #HBV

Will we see you in New York? The Precision team is in the city this week to participate in a panel discussion and fireside chat at the H.C. Wainwright 26th Annual Global Investment Conference! Register now for the fireside chat on September 10th at 5 p.m. ET. https://loom.ly/YGr5f_8 #GeneEditing #Biotech #DTIL #HCWainwrightGlobal

Precision BioSciences announced the maturity of a $13 million convertible note from its previously announced strategic transaction with Imugene Limited (ASX: IMU) for azercabtagene zapreleucel (azer-cel) in oncology. The proceeds to Precision include $9.75 million in cash and $3.25 million in Imugene ordinary shares. The addition of this cash further reinforces Precision’s expected cash runway into the second half of 2026. For more information, visit https://loom.ly/B7R3CFo #GeneEditing #Biotech #DTIL

Precision is presenting at the Sidoti Micro-Cap Investor Conference on August 15 at 10am ET! A live webcast of the presentation will be accessible on Precision’s website in the Investors section under Events & Presentations at https://lnkd.in/epAiWMAa. #GeneEditing #Biotech #DTIL

Precision BioSciences Reports Second Quarter 2024 Financial Results & Provides Business Update! Listen as Alex Kelly, Chief Financial Officer, shares the highlights. For the full report, visit https://loom.ly/6SPEl88 #GeneEditing #Biotech #DTIL

Precision is participating in BTIG's Biotech Conference on Monday, August 5 at 4PM ET! Join Michael Amoroso, President & Chief Executive Officer, and Cassie Gorsuch, VP of Gene Therapy, as they explore the utilization of Precision's innovative ARCUS® platform for advancing in vivo gene editing therapies. They will discuss its capabilities in achieving sophisticated gene edits such as insertion, excision, and elimination, aimed at transforming the landscape of genetic medicine. For more information, visit https://loom.ly/aPvoj_g #GeneEditing #Biotech #DTIL